Novartis news from FierceVaccines
NewsDynavax inks universal vaccine pact with Novartis
Dynavax Technologies and Novartis Vaccines and Diagnostics are teaming up on an effort to develop a new universal flu vaccine. Novartis Vaccines, which includes the old Chiron ops it bought out, will Read more...
Novartis yanks pre-pandemic vaccine application
Faced with a looming deadline to provide more data on the pre-pandemic vaccine Aflunov, Novartis Vaccines and Diagnostics has pulled its application for centralized marketing authorization from the Read more...
Novartis plans trials for growing vaccines pipeline
Novartis is taking the wraps off its vaccine pipeline, highlighting plans for new trials as it talks up a lineup of vaccine candidates. Researchers for the company detailed plans that include a Read more...
Novartis touts mid-stage results for MenB
Novartis says that a mid-stage study of its MenB vaccine demonstrated broad protection from meningococcal B infections in infants. Researchers tracked positive results starting with three Read more...
Novartis opens non-profit R&D vaccine center
One of the world's biggest pharma companies is breaking its business mold for its new R&D center for vaccines. Novartis is modeling its new vaccine development center in Italy on the Novartis Read more...
Novartis to offer data on pre-pandemic jabs
Novartis hasn't given up in its pursuit of profits. The Swiss company has been making an argument for use of its experimental flu vaccine ahead of any potential outbreak. Vaccines chief Jörg Read more...
Gene-mapping unlocks new generation of vaccines
Researchers at Novartis have made significant headway using gene-mapping tools to develop Read more...
| Press ReleasesNew data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants Data in JAMA show Menveo may provide infants protection against four of the most common Read more... PRESS RELEASE: Novartis launches strategic initiative to improve competitiveness in a changing healthcare environmenT Novartis launches strategic initiative to improve competitiveness in a dynamically changing healthcare environment "Forward" to simplify organizational structures, accelerate and Read more... PRESS RELEASE: Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Collaboration efforts will focus on the discovery and optimization of antibodies against a significant Read more... PRESS RELEASE: Tasigna gains European approval for patients with a life-threatening form of leukemia who are resistant or intol Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies Tasigna produced response in 49% of patients with Read more... PRESS RELEASE: Antisoma Shares Slide as Novartis Corporation (NVS) Sets up Avastin Fight Antisoma Shares Slide as Novartis Corporation Sets up Avastin Fight LONDON--Nov 20, 2007 -- ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Read more... |
Get more Novartis coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets